Document Detail

Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study.
MedLine Citation:
PMID:  16464988     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To evaluate the efficacy and safety of etanercept (ETN) monotherapy compared with combination ETN and methotrexate (MTX) treatment in patients with rheumatoid arthritis who had an inadequate response to MTX monotherapy. (The response was defined by the presence of Disease Activity Score-28 joint count (DAS28) >or=3.2 or a combination of >or=5 swollen joints, >or=5 painful joints and erythrocyte sedimentation rate >or=10 mm/h.)
METHODS: Patients with active rheumatoid arthritis taking MTX >or=12.5 mg/week for >or=3 months were included in this 16 week, randomised, open-label study. Patients were randomly assigned to either ETN (25 mg subcutaneous injection twice weekly) added to the baseline dose of MTX or ETN monotherapy.
RESULTS: 315 patients were randomised to ETN (n = 160) or ETN plus MTX (n = 155). The primary end point, DAS28 (4) improvement of >1.2 units, was achieved by 72.8% and 75.2% of patients treated with ETN and those treated with ETN plus MTX, respectively, with no significant difference (p = 0.658) between the two groups. The European League Against Rheumatism response criteria of good or moderate response was attained by 80.0% of patients in the ETN group and by 82.4% of patients in the ETN plus MTX group. American College of Rheumatology 20%, 50% and 70% response rates achieved by both groups were also similar: 71.0% v 67.1%, 41.9% v 40.1% and 17.4% v 18.4%, respectively. The rates of adverse and serious adverse events were similar between the treatment groups.
CONCLUSION: Both the addition of ETN to MTX and the substitution of ETN for MTX in patients with rheumatoid arthritis who had an inadequate response to MTX resulted in substantial improvements in clinical signs and symptoms and were generally well-tolerated treatment strategies for improving clinical signs and symptoms of rheumatoid arthritis.
P L C M van Riel; A J Taggart; J Sany; M Gaubitz; H W Nab; R Pedersen; B Freundlich; D MacPeek;
Related Documents :
23696018 - Long-term efficacy of a mini-course in radiation-reducing techniques in invasive cardio...
6512268 - Sister chromatid exchange in patients treated with methotrexate for psoriasis.
12375318 - "5d" outcome in 52 patients with rheumatoid arthritis surviving 20 years after initial ...
23240698 - An analysis of deep vein thrombosis in 1277 consecutive neurosurgical patients undergoi...
25143648 - Tibial lengthening for unilateral crowe type-iv developmental dysplasia of the hip.
1332988 - Comparative clinical and microbiological effects of topical subgingival application of ...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2006-02-07
Journal Detail:
Title:  Annals of the rheumatic diseases     Volume:  65     ISSN:  0003-4967     ISO Abbreviation:  Ann. Rheum. Dis.     Publication Date:  2006 Nov 
Date Detail:
Created Date:  2006-10-13     Completed Date:  2006-11-14     Revised Date:  2013-06-07    
Medline Journal Info:
Nlm Unique ID:  0372355     Medline TA:  Ann Rheum Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  1478-83     Citation Subset:  IM    
Radboud University Nijmegen Medical Centre, Department of Rheumatology, Geert Grooteplein 10, 6525 GA Nijmegen, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Arthritis, Rheumatoid / drug therapy*
Drug Therapy, Combination
Immunoglobulin G / therapeutic use*
Methotrexate / adverse effects,  therapeutic use*
Middle Aged
Prospective Studies
Receptors, Tumor Necrosis Factor / therapeutic use*
Severity of Illness Index
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Reg. No./Substance:
0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 0/Tumor Necrosis Factor-alpha; 185243-69-0/TNFR-Fc fusion protein; 59-05-2/Methotrexate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Definition of disease duration in ankylosing spondylitis: reassessing the concept.
Next Document:  A discussion of silver as an antimicrobial agent: alleviating the confusion.